Vanda Pharmaceuticals

VNDA

Market cap $441M

Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ: VNDA) concerning potential violations of the federal securities laws. Vanda issued a press release on January 8, 2026, "announc[ing] that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) concluding that the supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of jet lag disorder cannot be approved in its current form.

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

After losing some value lately, a hammer chart pattern has been formed for Vanda (VNDA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

LONDON & NEW YORK--(BUSINESS WIRE)--This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macro strategy provider announced they completed a definitive merger agreement. Under the terms of the agreement, Exante Data Inc will merge with and into Vanda through the acquisition by Vanda of all of the outstanding capital stock of Exante. Following the closing, Jens Nordvig will assume the role o.

WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) concluding that the supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of jet lag disorder cannot be approved in its current form. This letter stems from CDER's agreed re-review of the jet lag application under the October 1 collaborative framework agreement.

Vanda Pharmaceuticals is buy-rated following FDA approval of Nereus for motion sickness, with shares offering upside into 2026 catalysts. VNDA's Q3 saw strong Fanapt sales growth, but higher R&D and SG&A drove a $22.6M net loss, reflecting a strategic investment phase. The company maintains a robust $293.8M cash position, is guiding to $210–230M in 2025 revenue, and has ample runway to fund multiple late-stage launches.

The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.

Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.